http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
-
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
-
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
-
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
-
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
-
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
-
Personalis, Inc. (PSNL) Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
-
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
-
Personalis and Tempus Expand Collaboration to Biopharma
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis Reports Third Quarter 2024 Financial Results
-
Personalis to Present at the Stifel 2024 Healthcare Conference
-
Personalis to Announce Third Quarter 2024 Financial Results
-
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
-
Personalis and Tempus Announce Expanded Collaboration
-
Personalis Reports Second Quarter 2024 Financial Results
-
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
-
Personalis to Announce Second Quarter 2024 Financial Results
-
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
-
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
-
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
-
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
-
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
-
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Reports First Quarter 2024 Financial Results
-
Personalis to Announce First Quarter 2024 Financial Results
-
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
-
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
-
Personalis to Participate at Upcoming Investor Conferences
-
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
-
Personalis (PSNL) Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
-
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
-
Personalis, Inc. (PSNL) discloses reduction in headcount impacting approximately 20%
-
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
-
Personalis, Inc. (PSNL) and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
-
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
-
Myriad Genetics (MYGN) and Personalis Partner to Market Solutions to Pharma Customers
-
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
-
Personalis Reports Third Quarter 2023 Financial Results
